A new prospective, randomized controlled study has identified topical nitroglycerin as a safe and effective intervention for reducing the incidence of skin flap necrosis following modified radical mastectomy (MRM). The research, conducted at Stanley Medical College and Hospital in Chennai, India, found that patients treated with 2% nitroglycerin ointment experienced a significantly lower rate of flap necrosis compared to those receiving conventional povidone-iodine treatment. The findings, published in the journal Cureus, suggest that this simple, cost-effective topical therapy could improve postoperative recovery and reduce the need for secondary surgical interventions in breast cancer patients.
Skin flap necrosis remains a persistent challenge in breast cancer surgery, often leading to wound breakdown, infection, and delays in essential adjuvant therapies like chemotherapy or radiation. By leveraging the nitric oxide-mediated vasodilatory properties of nitroglycerin, researchers aimed to enhance microvascular perfusion in the delicate skin flaps raised during mastectomy. The study provides clinical evidence that early postoperative application of the ointment can mitigate ischemic tissue damage, potentially transforming standard wound care protocols for patients undergoing these procedures.
Study Methodology and Patient Cohort
The study enrolled 60 female patients scheduled for modified radical mastectomy, randomly assigning them into two equal groups of 30. The intervention group received 2% nitroglycerin ointment, while the control group was treated with povidone-iodine. Treatment was initiated on the second postoperative day, a timing selected to ensure initial flap viability while providing intervention during the critical window when ischemic complications typically manifest. The application involved approximately 0.3 inches of ointment, applied three times daily for one week.
To ensure the integrity of the results, the study employed an assessor-blinded design. Independent consultant surgeons, who were unaware of the treatment allocation, evaluated the patients at regular intervals over a four-week follow-up period. Standardized digital photography was used to document wound status, and the study was registered with the Clinical Trials Registry of India, adhering to the ethical standards of the Declaration of Helsinki.
Significant Reduction in Flap Necrosis
The primary outcome of the study was the incidence of skin flap necrosis within four weeks post-surgery. The results were striking: only two patients (6.7%) in the nitroglycerin group developed necrosis, compared to 10 patients (33.3%) in the control group. This represents an 80% relative risk reduction, a statistically significant finding (p=0.028) that underscores the potential clinical utility of the intervention.
Beyond the primary incidence rate, the study evaluated the severity of tissue damage. Full-thickness necrosis was observed exclusively in the control group, and the mean necrotic area was significantly smaller among those treated with nitroglycerin. These findings suggest that even when necrosis occurs, the application of nitroglycerin may limit the extent of tissue loss, thereby reducing the overall morbidity associated with the complication.
Impact on Wound Healing and Recovery
Secondary outcomes further highlighted the benefits of the nitroglycerin intervention. Patients in the treatment group demonstrated significantly faster wound healing times and a lower incidence of delayed wound healing compared to the control group. The mean time to complete epithelialization was 16.9 days for the nitroglycerin group, compared to 21.2 days for the control group, a difference that reached statistical significance (p=0.002).
While the requirement for surgical debridement and secondary suturing was numerically lower in the nitroglycerin group, these specific secondary measures did not reach statistical significance. Similarly, while surgical site infection rates and hospital stays were lower for the intervention group, the researchers noted that these outcomes are influenced by a multitude of patient- and procedure-related factors, and the study's sample size may have limited the power to detect significant differences in these areas.
Safety Profile and Clinical Implications
Topical nitroglycerin was found to be well-tolerated by the study participants. Headache was the most frequently reported adverse event, occurring in 16.7% of the nitroglycerin group compared to 3.3% in the control group, though this difference was not statistically significant. Other reported side effects, such as dizziness, flushing, and local skin irritation, were infrequent, mild, and self-limiting. No patients required discontinuation of the treatment, reinforcing the safety profile of the intervention.
The researchers concluded that topical nitroglycerin represents a practical, affordable, and effective adjunct to standard postoperative care. By improving microvascular blood flow, the treatment addresses the underlying mechanism of flap ischemia. The study authors advocate for further multicenter trials to validate these results and to establish standardized protocols for the routine use of topical nitroglycerin in clinical practice, particularly in resource-constrained settings where minimizing postoperative complications is vital for maintaining the continuity of cancer care.
